Speaker Details

BIOGRAPHY

Amer-Denis Akkad is the Head of Translational Research at Absci, a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. He is a biochemist by training and received his Ph.D. in Neuroscience at the IGSN in Bochum. After his additional training as a clinical laboratory geneticist, he joined Bayer AG as a drug hunter covering the value chain from early target ID to pre-clinical candidate stage. During this time, he spent 4 years at the Broad Institute of MIT and Harvard building up and leveraging the Precision Cardiology Laboratory initiative for high-resolution single sequencing to broaden the understanding of underlying disease mechanisms and to facilitate the development of new therapeutic interventions. In his current role he is amongst others ensuring that the differentiated antibody drug candidates which are created using Absci’s de novo AI model transition successfully towards the clinic.